United States Patent 8,668,931: Scope, Claims Architecture, and US Landscape

US Drug Patent 8,668,931 protects a fixed-dose oral tablet that combines metformin hydrochloride (controlled release) with pioglitazone hydrochloride (immediate release layer). The claims are drafted around three technical pillars: (1) a metformin-only controlled-release core, (2) an immediate-release pioglitazone layer with specific formulation/excipients and tight impurity limits, and (3) functional release and stability performance defined by USP apparatus and specified dissolution/impurity thresholds.

What does the patent claim, in plain scope terms?

The protected subject matter is limited to a tablet with the following combination:

Metformin hydrochloride: present as the only drug in the controlled-release core (plus excipients), with release controlled by a sustained release coating and optionally an inner seal coating.
Pioglitazone hydrochloride: present as an immediate-release layer surrounding the controlled-release core (or the seal/sustained layer if present).
Outer seal (optional): a non-drug, water-dispersing/dissolving outer seal layer.
Performance: explicit dissolution profiles and USP 26 Apparatus 1 immediate release requirements for pioglitazone at pH 2.0 and explicit impurity limits for pioglitazone-related compounds, including post-storage impurity constraints.
Material constraints: in some dependent claims, the controlled-release metformin core is substantially free of gelling or expanding polymer, and the controlled release is described as osmotic.

This creates a relatively narrow but technically detailed scope that targets a specific layering strategy: metformin is engineered for extended release, while pioglitazone is engineered to release rapidly in gastric conditions.

How are the independent claims structured and what is their claim boundary?

Claim 1 (core architecture + pioglitazone dissolution + impurity/stability gates)

Claim 1 is the primary independent claim. It requires:

A. Tablet containing two drugs via distinct release domains

Controlled release core:
- Core contains about 500 mg to about 1000 mg of only one drug, i.e., metformin hydrochloride, plus at least one pharmaceutically acceptable excipient.
- Optional inner seal coating around the core.
- Sustained release coating around the core or around the inner seal coating if present.
Optional outer seal coating:
- Does not contain an active pharmaceutical ingredient.
- Rapidly disperses or dissolves in water.
Immediate release pioglitazone layer around:
- the sustained release coating, or
- the outer seal coating if present.

B. Pioglitazone immediate release layer formulation limits

Pioglitazone hydrochloride amount: about 15 mg to about 45 mg.
Binder (choose from):
- polyvinyl pyrrolidone
- hydroxypropyl cellulose
- hydroxyethylcellulose
- hydroxypropyl methylcellulose
- ethylcellulose
- polymethacrylate
- polyvinylalcohol
- waxes (and mixtures)
Pore former (choose from):
- sodium chloride
- potassium chloride
- sucrose
- sorbitol
- mannitol
- polyethylene glycols
- propylene glycol (and mixtures)
Optional pharm excipient selected from:
- surfactants, absorption enhancers, plasticizers, antifoaming agents, and combinations.

C. Pioglitazone in vitro performance gate

Release condition: USP 26, Apparatus 1, 100 rpm, 37°C, 900 ml of 0.3 M KCl-HCl buffer, pH 2.0.
Release threshold:
- not less than 75% of pioglitazone hydrochloride released within 45 minutes
Stability/impurity gate:
- After storage 40°C / 75% RH for three months,
- total pioglitazone-related compounds/impurities ≤ 0.6% (HPLC)
- each individual impurity ≤ 0.25%
- impurity list is enumerated with five specific named compounds.

This is a functional claim that is tightly coupled to both release testing and quantitative impurity acceptance criteria after accelerated storage.

Claim 12 (independent claim with dissolution profile for metformin core)

Claim 12 is an additional independent claim that largely repeats the layered architecture and pioglitazone layer constraints, but replaces or complements claim 1 by adding a detailed metformin dissolution profile in USP Type 2 (paddle) at pH 7.5.

Key deltas in Claim 12:

Adds a metformin controlled release dissolution profile in USP Type 2, 75 rpm, 900 ml simulated intestinal fluid, pH 7.5, 37°C:
- 0-25% released after 2 hours
- 10-45% after 4 hours
- 30-90% after 8 hours
- ≥50% after 12 hours
- ≥60% after 16 hours
- ≥70% after 20 hours
Pioglitazone immediate release gate is also included, but the claim phrasing tightens the impurity limit set:
- pioglitazone layer releases ≥75% within 45 minutes (same USP apparatus/conditions as claim 1)
- and the tablet contains not more than 0.25% of the enumerated impurity set (presented as a combined constraint on the listed compounds, with each compound appearing in the list).

This makes Claim 12 effectively enforceable against formulations that hit the metformin extended-release profile as defined in USP Type 2, while also meeting the same basic layered immediate-release pioglitazone requirements.

What are the dependent claim layers that narrow scope (release thresholds, impurities, and core mechanics)?

Pioglitazone release strengthening (dependent claims 2, 13, 14)

Across claim sets:

Claim 2: ≥85% pioglitazone within 45 minutes (USP 26 Apparatus 1, pH 2.0 conditions as specified)
Claim 13: same ≥85% requirement for Claim 12-dependent formulation
Claim 14: 100% pioglitazone within 45 minutes for Claim 12-dependent formulation

These dependents escalate enforceability to products that materially outperform the base “≥75%” gate.

Pioglitazone impurity tightening (dependent claims 3-5, 4-5; and 17-18 for Claim 12)

For Claim 1-based lineage:

Claim 3: total pioglitazone-related compounds/impurities ≤0.5%
Claim 4: each impurity ≤0.20%
Claim 5: each impurity ≤0.10%

For Claim 12-based lineage (claims 17-18), the dependent claims narrow the impurity amounts for the listed compounds:

Claim 17: tablet contains not more than 0.2% of the listed compounds (each compound is included in the list in the claim text)
Claim 18: tablet contains not more than 0.1% of the listed compounds

This indicates that the application is crafted to withstand challenges on both release behavior and stability-related impurity formation.

Metformin controlled-release mechanism: osmotic and polymer-free (claims 6, 7, 8, 15, 16)

Claim 6: controlled release core is an osmotic tablet
Claim 7: osmotic tablet is more explicitly defined:
- metformin core composition:
  - 50-98% metformin hydrochloride
  - 0.1-40% binding agent
  - 0-20% absorption enhancer
  - 0-5% lubricant
- optional inner seal coat
- sustained release membrane:
  - 50-99% polymer
  - 0-40% flux enhancer
  - 0-25% plasticizer
  - includes at least one passageway for metformin release
Claim 8: controlled release core is substantially free of gelling or expanding polymer
Claim 15 (Claim 12 lineage): same “substantially free” limitation
Claim 9 (release performance): metformin controlled release gives Tmax 8-12 hours
Claim 16 (Claim 12 lineage alternative dissolution ranges): different USP Type 2 dissolution bands:
- 0-15% at 2 hours
- 20-40% at 4 hours
- 45-90% at 8 hours
- ≥60% at 12 hours
- ≥70% at 16 hours
- ≥80% at 20 hours

The dependent claim design suggests two alternative metformin extended-release window sets (Claim 12’s base profile and Claim 16’s tighter/shifted bands), while maintaining the same pioglitazone immediate-release and impurity gates.

Pioglitazone Tmax specification (claims 10, 11)

Claim 10: pioglitazone release provides Tmax 1-12 hours
Claim 11: pioglitazone release provides Tmax 1-4 hours

These dependents push toward fast in vivo exposure timing and can narrow design-arounds that hit dissolution but not pharmacokinetic timing.

Where does the tightest enforceability sit? (release + impurity + “only one drug in core”)

From a freedom-to-operate standpoint, the scope is constrained by at least four high-friction claim elements:

Metformin-only drug in core
- Claim 1/12 require the core has “only one drug” which is metformin hydrochloride. Mixing another active in the controlled-release core is outside claim scope.
Layered tablet architecture
- Pioglitazone must be in an immediate release layer surrounding the controlled release core/sustained coating, not simply mixed into the core or co-released.
USP-defined pioglitazone release in gastric-like pH
- USP 26 Apparatus 1, pH 2.0, 900 ml, 100 rpm, 37°C, with ≥75% within 45 minutes, and optionally raised to ≥85% or 100% depending on which dependent claim is asserted.
Enumerated pioglitazone impurity set with quantitative acceptance limits
- Claim 1 requires not just low impurity but low impurity after storage with explicit total and individual limits and a defined set of five named compounds.

These are not “design-space” claims only; they are “product performance” claims with chemical-spec and test-method anchors.

How does the claim set map to product design variables (a landscape view for design-arounds)?

Below is a variable map consistent with typical layered fixed-dose combination tablet design. It shows which variables are directly constrained by 8,668,931.

Design variable	What the patent requires	Claim impact
Core drug content	500 mg to 1000 mg metformin hydrochloride; “only one drug”	Hard carve-in
Metformin release method	Sustained coating around core; optional osmotic membrane with passageways	Mechanism-dependent narrowing (claims 6-7)
Metformin polymer behavior	“Substantially free of gelling or expanding polymer”	Extra narrowing (claims 8, 15)
Metformin extended-release profile	USP Type 2 dissolution bands at pH 7.5 (claims 12, 16) and Tmax 8-12 hours (claim 9)	Hard performance window
Pioglitazone layer position	Immediate release layer surrounding the sustained coating/outer seal	Architecture lock
Pioglitazone dose	15 mg to 45 mg	Hard numerical range
Pioglitazone binder/pore former choices	Restricted lists (binders and pore formers)	Formulation constrained
Pioglitazone release test	USP 26 Apparatus 1, pH 2.0, ≥75% in 45 min (plus dependents)	Hard gate
Pioglitazone impurities	Enumerated compound list; total and individual limits after 40°C/75% RH 3 months	Chemical spec and stability lock

What is the broader US patent landscape for this combination?

This claim set is built to cover a specific product design approach: metformin extended release paired with pioglitazone immediate release in a single tablet, with USP-based dissolution and pioglitazone impurity management. In the US landscape, this typically overlaps with three clusters of intellectual property:

Fixed-dose combination patents for metformin + pioglitazone
Modified-release tablet technology (osmotic systems, bilayer/multilayer release strategies, seal coatings)
Formulation patents defined by drug-specific impurities and dissolution/PK windows

However, without the publication family, priority dates, related US continuations, and the list of other US patents in force that cite or overlap with 8,668,931, the actionable landscape cannot be completed to the level required to determine the strength of blocking positions, likely litigation targets, or remaining design-around freedom.

No further US landscape conclusions are provided here because the prompt does not include the patent document metadata (title, assignee, priority, filing/publication numbers), nor does it provide other patent numbers, examiner citations, or prosecution history that would allow accurate mapping of the competitive patent positions.

Practical scope summary (what competitors should assume is covered)

If a competitor makes a metformin/pioglitazone tablet that:

uses a metformin-controlled-release core where the core drug is metformin hydrochloride in the 500-1000 mg range,
includes an immediate-release pioglitazone layer with 15-45 mg pioglitazone hydrochloride,
meets USP pH 2.0 rapid release for pioglitazone (≥75% in 45 minutes, and potentially higher),
and meets enumerated pioglitazone impurity limits after accelerated storage,

then the product is at minimum within the independent claim set and may also fall under higher enforceability dependent claims depending on the exact impurity percentages and release performance.

Key Takeaways

US 8,668,931 protects a layered fixed-dose metformin/pioglitazone tablet with metformin controlled release and pioglitazone immediate release.
The scope is constrained by specific USP test conditions and by quantitative, enumerated pioglitazone impurity limits after storage.
Dependent claims narrow to higher pioglitazone release, tighter impurity thresholds, and metformin mechanisms including osmotic passageway membranes and polymer-free behavior, plus specific metformin dissolution windows.
The claim drafting strongly favors enforceability against products that hit both dissolution performance and stability-related impurity specifications.

FAQs

1) Does the patent cover co-mixing pioglitazone with metformin in the same core?
No. The claims require the metformin controlled-release core to contain “only one drug” being metformin hydrochloride, while pioglitazone is in a separate immediate release layer surrounding the core/sustained coating.

2) What makes the pioglitazone constraints unusual versus typical release-only modified-release patents?
The claims include enumerated pioglitazone-related impurity compounds with quantified acceptance limits and a post-storage requirement after 40°C/75% RH for three months, using HPLC thresholds.

3) What dissolution setup is used to test pioglitazone release?
USP 26, Apparatus 1 at 100 rpm, 37°C, with 900 ml of 0.3 M KCl-HCl buffer, pH 2.0, measuring pioglitazone release within 45 minutes.

4) What are the metformin dissolution tests in the dependent claims?
For Claim 12 and claim 16: USP Type 2 at 75 rpm, 900 ml simulated intestinal fluid at pH 7.5, 37°C, with specific banded release percentages at 2, 4, 8, 12, 16, and 20 hours.

5) Does the patent require an osmotic design?
No. Osmotic tablets are required only in dependent claim 6 and more specifically defined in dependent claim 7. Independent claims cover the layered concept with sustained coating; osmotic structure narrows further.

References

[1] United States Patent 8,668,931. Claims as provided in the prompt.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	054238	⤷ Start Trial
Australia	2003272504	⤷ Start Trial
Australia	2004283059	⤷ Start Trial
Australia	2006232993	⤷ Start Trial
Australia	2011202162	⤷ Start Trial
Brazil	PI0414471	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,668,931

Summary for Patent: 8,668,931